[Therapeutic agents for disorders of bone and calcium metabolism: ED-71].
ED-71 is a new vitamin D receptor ligand, bearing a hydroxypropoxy substituent at the 2beta-position of 1alpha, 25 (OH) (2)D(3). In ovariectomized rats, ED-71 increased lumbar vertebral bone mass and bone strength by inhibiting bone resorption and maintaining bone formation without causing hypercalcemia. In a randomized, placebo-controlled, double-blinded clinical trial for osteoporotic subjects with sufficient vitamin D supply, ED-71 treatment for 12 months can effectively increase lumbar and hip bone mineral density in a dose-dependent manner without causing sustained hypercalcemia. Serum calcium (Ca) and urinary Ca excretion was increased dose-dependently by ED-71 treatment, but it was in normal range. These results demonstrate that ED-71 can effectively increase bone mass without causing hypercalcemia, and suggest that ED-71 can be a promising candidate for the treatment of osteoporosis.